Mucosal treatments for herpes simplex virus

Insights on targeted immunoprophylaxis and therapy

Chris L. McGowin, Richard Pyles

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Herpes simplex virus (HSV) serotypes 1 and 2 establish lifelong infections that can produce reactivated pools of virus at mucosal sites where primary infections were initiated. No approved vaccines are available. To break the transmission cycle, interventions must either prevent infection or reduce infectivity at mucosal sites. This article discusses the recent experimental successes of immunoprophylactic and therapeutic compounds that enhance resistance and/or reduce viral loads at genital and ocular mucosa. Current data indicate Toll-like receptor agonists and selected immunomodulating compounds effectively increase the HSV infection threshold and hold promise for genital prophylaxis. Similarly, immunization at genital and extragenital mucosal sites is discussed. Finally, preclinical success with novel immunotherapies for ocular HSV that address herpetic keratitis and corneal blindness is reviewed.

Original languageEnglish (US)
Pages (from-to)15-22
Number of pages8
JournalFuture Microbiology
Volume5
Issue number1
DOIs
StatePublished - Jan 2010
Externally publishedYes

Fingerprint

Simplexvirus
Herpetic Keratitis
Infection
Human Herpesvirus 2
Toll-Like Receptors
Human Herpesvirus 1
Virus Diseases
Blindness
Viral Load
Immunotherapy
Immunization
Mucous Membrane
Therapeutics
Vaccines
Viruses

Keywords

  • Genital herpes immunotherapy
  • Herpes simplex
  • HSV-1
  • HSV-2
  • Keratitis mucosa
  • Therapy
  • TLR

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this

Mucosal treatments for herpes simplex virus : Insights on targeted immunoprophylaxis and therapy. / McGowin, Chris L.; Pyles, Richard.

In: Future Microbiology, Vol. 5, No. 1, 01.2010, p. 15-22.

Research output: Contribution to journalArticle

@article{43467ba682dc4ec385848024964ec7ab,
title = "Mucosal treatments for herpes simplex virus: Insights on targeted immunoprophylaxis and therapy",
abstract = "Herpes simplex virus (HSV) serotypes 1 and 2 establish lifelong infections that can produce reactivated pools of virus at mucosal sites where primary infections were initiated. No approved vaccines are available. To break the transmission cycle, interventions must either prevent infection or reduce infectivity at mucosal sites. This article discusses the recent experimental successes of immunoprophylactic and therapeutic compounds that enhance resistance and/or reduce viral loads at genital and ocular mucosa. Current data indicate Toll-like receptor agonists and selected immunomodulating compounds effectively increase the HSV infection threshold and hold promise for genital prophylaxis. Similarly, immunization at genital and extragenital mucosal sites is discussed. Finally, preclinical success with novel immunotherapies for ocular HSV that address herpetic keratitis and corneal blindness is reviewed.",
keywords = "Genital herpes immunotherapy, Herpes simplex, HSV-1, HSV-2, Keratitis mucosa, Therapy, TLR",
author = "McGowin, {Chris L.} and Richard Pyles",
year = "2010",
month = "1",
doi = "10.2217/fmb.09.111",
language = "English (US)",
volume = "5",
pages = "15--22",
journal = "Future Microbiology",
issn = "1746-0913",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Mucosal treatments for herpes simplex virus

T2 - Insights on targeted immunoprophylaxis and therapy

AU - McGowin, Chris L.

AU - Pyles, Richard

PY - 2010/1

Y1 - 2010/1

N2 - Herpes simplex virus (HSV) serotypes 1 and 2 establish lifelong infections that can produce reactivated pools of virus at mucosal sites where primary infections were initiated. No approved vaccines are available. To break the transmission cycle, interventions must either prevent infection or reduce infectivity at mucosal sites. This article discusses the recent experimental successes of immunoprophylactic and therapeutic compounds that enhance resistance and/or reduce viral loads at genital and ocular mucosa. Current data indicate Toll-like receptor agonists and selected immunomodulating compounds effectively increase the HSV infection threshold and hold promise for genital prophylaxis. Similarly, immunization at genital and extragenital mucosal sites is discussed. Finally, preclinical success with novel immunotherapies for ocular HSV that address herpetic keratitis and corneal blindness is reviewed.

AB - Herpes simplex virus (HSV) serotypes 1 and 2 establish lifelong infections that can produce reactivated pools of virus at mucosal sites where primary infections were initiated. No approved vaccines are available. To break the transmission cycle, interventions must either prevent infection or reduce infectivity at mucosal sites. This article discusses the recent experimental successes of immunoprophylactic and therapeutic compounds that enhance resistance and/or reduce viral loads at genital and ocular mucosa. Current data indicate Toll-like receptor agonists and selected immunomodulating compounds effectively increase the HSV infection threshold and hold promise for genital prophylaxis. Similarly, immunization at genital and extragenital mucosal sites is discussed. Finally, preclinical success with novel immunotherapies for ocular HSV that address herpetic keratitis and corneal blindness is reviewed.

KW - Genital herpes immunotherapy

KW - Herpes simplex

KW - HSV-1

KW - HSV-2

KW - Keratitis mucosa

KW - Therapy

KW - TLR

UR - http://www.scopus.com/inward/record.url?scp=75849117856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75849117856&partnerID=8YFLogxK

U2 - 10.2217/fmb.09.111

DO - 10.2217/fmb.09.111

M3 - Article

VL - 5

SP - 15

EP - 22

JO - Future Microbiology

JF - Future Microbiology

SN - 1746-0913

IS - 1

ER -